Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5654921 | Clinical Immunology | 2017 | 11 Pages |
Abstract
It was previously demonstrated that N-glycosylation improved IFN-α pharmacokinetic properties. Here, we further reduce immunogenicity as measured in vitro using T cell assays and cytokine profiling by modifying the T cell epitope content of a protein (de-immunizing). Taking into consideration the present results and previously reported immunogenicity data for commercial IFN-α2b variants, 4N-IFN(VAR1) and 4N-IFN-4N(VAR3) appear to be promising candidates for improved IFN-α therapy of HCV and HBV.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Eduardo F. Mufarrege, SofÃa Giorgetti, Marina Etcheverrigaray, Frances Terry, William Martin, Anne S. De Groot,